Torin 1

For research use only.

Catalog No.S2827

115 publications

Molecular Weight(MW): 607.62

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

Selleck's Torin 1 has been cited by 115 publications

Nat Biotechnol, 2020, 38(5):638-648

PubMed: 32249828 ( click the link to review the publication )

Cell, 2019, 177(4):896-909

PubMed: 31030999 ( click the link to review the publication )

Nat Immunol, 2018, 19(12):1330-1340

PubMed: 30420624 ( click the link to review the publication )

Nat Immunol, 2018, 19(12):1330-1340

PubMed: 30420624 ( click the link to review the publication )

Cell Metab, 2018, 28(3):369-382

PubMed: 30043754 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Nat Commun, 2020, 24;11(1):479

PubMed: 31980602 ( click the link to review the publication )

Autophagy, 2020, 15:1-13

PubMed: 32264736 ( click the link to review the publication )

Cell Rep, 2020, 30(5):1400-1416

PubMed: 32023458 ( click the link to review the publication )

Cell Rep, 2020, 30(6):1835-1847

PubMed: 32049014 ( click the link to review the publication )

Cell Death Dis, 2020, 8;5:e1214

PubMed: 24810050 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439931 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786

PubMed: 32169890 ( click the link to review the publication )

Int J Mol Sci, 2020, 24;21(6) pii: E2240

PubMed: 32213867 ( click the link to review the publication )

Exp Cell Res, 2020, 10.1016/j.yexcr.2020.111981

PubMed: 32234375 ( click the link to review the publication )

Nat Metab, 2020, 2(1):41-49

PubMed: 31993556 ( click the link to review the publication )

Cancer Res, 2020, 80(3):444-457

PubMed: 31722999 ( click the link to review the publication )

Mol Cell, 2019, 73(4):788-802

PubMed: 30704899 ( click the link to review the publication )

Mol Cell, 2019, 73(4):788-802

PubMed: 30704899 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4741

PubMed: 31628323 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1693

PubMed: 30979895 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5681

PubMed: 31831743 ( click the link to review the publication )

Autophagy, 2019, 15(3):493-509

PubMed: 30304977 ( click the link to review the publication )

Autophagy, 2019, 1-13

PubMed: 30957628 ( click the link to review the publication )
Autophagy, 2019, 15(3):493-509

PubMed: 30304977 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1703353

PubMed: 31847700 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1628536

PubMed: 31203721 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 10.1073/pnas.1911393116

PubMed: 31732667 ( click the link to review the publication )

Cell Rep, 2019, 29(3):589-602

PubMed: 31618629 ( click the link to review the publication )

Cell Rep, 2019, 27(7):2075-2091.e5

PubMed: 31091447 ( click the link to review the publication )

Cell Mol Immunol, 2019, 10.1038/s41423-019-0281-6

PubMed: 31467416 ( click the link to review the publication )

Oncogene, 2019, 38(10):1639-1650

PubMed: 30337688 ( click the link to review the publication )

Oncogene, 2019, 10.1038/s41388-019-1085-y

PubMed: 31685947 ( click the link to review the publication )

Oncogene, 2019, 38(2):209-227

PubMed: 30087437 ( click the link to review the publication )

Oncogene, 2019, 38(2):209-227

PubMed: 30087437 ( click the link to review the publication )

Oncogene, 2019, 10.1038/s41388-019-1085-y

PubMed: 31685947 ( click the link to review the publication )

EBioMedicine, 2019, 40:151-162

PubMed: 30711516 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):399

PubMed: 31113939 ( click the link to review the publication )

Lab Invest, 2019, 99(5):648-658

PubMed: 30679758 ( click the link to review the publication )

Biochem Pharmacol, 2019, 162:191-201

PubMed: 30471247 ( click the link to review the publication )

J Biol Chem, 2019, 294(10):3760-3771

PubMed: 30617181 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 519(4):909-915

PubMed: 31563324 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4831

PubMed: 30446646 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5426

PubMed: 30575721 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2819

PubMed: 30026551 ( click the link to review the publication )

J Pathol, 2018, 245(2):235-248

PubMed: 29570219 ( click the link to review the publication )

PLoS Genet, 2018, 14(5):e1007369

PubMed: 29750810 ( click the link to review the publication )

Development, 2018, 145(18)

PubMed: 30126904 ( click the link to review the publication )
Lung Cancer, 2018, 120:34-45

PubMed: 29748013 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Exp Cell Res, 2018, 363(1):84-94

PubMed: 29289595 ( click the link to review the publication )

Braz J Med Biol Res, 2018, 51(6):e7080

PubMed: 29694502 ( click the link to review the publication )

Cell Res, 2017, 27(2):184-201

PubMed: 27934868 ( click the link to review the publication )

Mol Cell, 2017, 67(6):907-921

PubMed: 28844862 ( click the link to review the publication )

Mol Cell, 2017, 65(6):1029-1043

PubMed: 28306502 ( click the link to review the publication )

Nat Commun, 2017, 8:15045

PubMed: 28429794 ( click the link to review the publication )

Autophagy, 2017, 13(8):1364-1385

PubMed: 28598230 ( click the link to review the publication )

Autophagy, 2017, 13(4):686-702

PubMed: 28121484 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )

PLoS Pathog, 2017, 13(3):e1006249

PubMed: 28249048 ( click the link to review the publication )

Sci Rep, 2017, 7(1):13832

PubMed: 29062139 ( click the link to review the publication )

J Biol Chem, 2017, 292(35):14544-14555

PubMed: 28684424 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2017, 313(5):C501-C515

PubMed: 28794108 ( click the link to review the publication )

J Agric Food Chem, 2017, 65(31):6625-6637

PubMed: 28697598 ( click the link to review the publication )

Radiat Res, 2017, 187(3):382-396

PubMed: 28327001 ( click the link to review the publication )

Oncotarget, 2017, 8(65):109848-109856

PubMed: 29312653 ( click the link to review the publication )

Oncotarget, 2017, 8(55):93688-93703

PubMed: 29212182 ( click the link to review the publication )

Oncotarget, 2017, 8(52):89527-89538

PubMed: 29163768 ( click the link to review the publication )

Oncotarget, 2017, 8(65):109848-109856

PubMed: 29312653 ( click the link to review the publication )

Oncotarget, 2017, 8(27):44550-44566

PubMed: 28562352 ( click the link to review the publication )

Protein Cell, 2016, 7(12):878-887

PubMed: 27909983 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(12):3535-3551

PubMed: 28077803 ( click the link to review the publication )
Stem Cells Transl Med, 2016, 5(5):580-90

PubMed: 27025692 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(5):1428-37

PubMed: 26938669 ( click the link to review the publication )

Mol Biol Cell, 2016, 27(2):321-33

PubMed: 26582390 ( click the link to review the publication )

J Biol Chem, 2016, 291(33):17467-77

PubMed: 27339899 ( click the link to review the publication )

J Cell Physiol, 2016, 10.1002/jcp.25456

PubMed: 27301841 ( click the link to review the publication )

Front Plant Sci, 2016, 7:1746

PubMed: 27917191 ( click the link to review the publication )

BMC Musculoskelet Disord, 2016, 17:150

PubMed: 27052304 ( click the link to review the publication )

Oncotarget, 2016, 7(34):55690-55703

PubMed: 27494886 ( click the link to review the publication )

Oncotarget, 2016, 7(36):57525-57544

PubMed: 27438153 ( click the link to review the publication )

J Clin Invest, 2015, 125(3):1174-88

PubMed: 25664849 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 25846574 ( click the link to review the publication )

J Med Chem, 2015, 58(16):6559-73

PubMed: 26237138 ( click the link to review the publication )

Cell Commun Signal, 2015, 13:15

PubMed: 25849580 ( click the link to review the publication )

J Cell Physiol, 2015, 230(5):1064-74

PubMed: 25283437 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: 25582703 ( click the link to review the publication )

J Virol, 2015, 89(1):626-42

PubMed: 25339775 ( click the link to review the publication )

J Virol, 2015, 89(1):626-42

PubMed: 25339775 ( click the link to review the publication )

Sci Rep, 2015, 5:13891

PubMed: 26403635 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074/jbc.M114.621706

PubMed: 25878248 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: 25561726 ( click the link to review the publication )

Cell Signal, 2015, 27(8):1557-68

PubMed: 25936523 ( click the link to review the publication )

BMC Cancer, 2015, 15:855

PubMed: 26542945 ( click the link to review the publication )

BMC Cancer, 2015, 15:855

PubMed: 26542945 ( click the link to review the publication )
PLoS One, 2015, 10(8):e0135614

PubMed: 26267903 ( click the link to review the publication )

Oncotarget, 2015, 6(27):23238-48

PubMed: 26177051 ( click the link to review the publication )

Oncotarget, 2015, 6(27):23238-48

PubMed: 26177051 ( click the link to review the publication )

PLoS Pathog, 2014, 10(6):e1004196

PubMed: 24945378 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1214

PubMed: 24810050 ( click the link to review the publication )

Am J Pathol, 2014, 184(1):214-29

PubMed: 24215913 ( click the link to review the publication )

J Biol Chem, 2014, 289(43):29739-49

PubMed: 25164809 ( click the link to review the publication )

J Biol Chem, 2014, 289(25):17830-42

PubMed: 24798333 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(24):4474-84

PubMed: 25288641 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.05.047

PubMed: 24858682 ( click the link to review the publication )

Oncotarget, 2014, 5(24):12715-27

PubMed: 25587030 ( click the link to review the publication )

Oncotarget, 2014, 5(24):12715-27

PubMed: 25587030 ( click the link to review the publication )

Oncotarget, 2014, 5(16):6816-31

PubMed: 25149175 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Blood, 2013, 121(18):3619-30

PubMed: 23444404 ( click the link to review the publication )

Trends Microbiol, 2013, 21(6):286-95

PubMed: 23608036 ( click the link to review the publication )

Genes Dev, 2013, 27(10):1115-31

PubMed: 23699409 ( click the link to review the publication )

PLoS One, 2013, 8(11):e80070

PubMed: 24244612 ( click the link to review the publication )

EMBO Mol Med, 2011, 3(4):189-200

PubMed: 21412983 ( click the link to review the publication )

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

Targets

mTORC1 ^[1] (Cell-free assay)	mTOR ^[2] (Cell-free assay)	DNA-PK ^[2] (Cell-free assay)	mTORC2 ^[1] (Cell-free assay)	p110γ ^[2] (Cell-free assay)	View More
2 nM	4.32 nM	6.34 nM	10 nM	171 nM	View More

In vitro

Torin1 inhibits phosphorylation of mTORC1 and mTORC2 substrates in cells at concentrations of 2 and 10 nM, respectively. Moreover, Torin1 exhibits 1000-fold selectivity for mTOR over PI3K (EC50 = 1800 nM) and exhibits 100-fold binding selectivity relative to 450 other protein kinases. ^[1] ^[2] Torin1 causes cell cycle arrest through a rapamycin-resistant mechanism that is also independent of mTORC2. Torin1 disrupts mTORC1-dependent phenotypes more completely than rapamycin. Rapamycin-resistant functions of mTORC1 are required for cap-dependent translation. ^[1] In a recent study, it is reported Torin1 increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
ETK-1	NXfwPI1qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmriTWM2OD1yLkCwNFMxPiEQvF2=	MnLzV2FPT0WU
OCUB-M	NETJbYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DxUGlEPTB;MD6wNFE6PCEQvF2=	NWLUeIJPW0GQR1XS
DOHH-2	NWnvXXI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3Xuc2lEPTB;MD6wNFIzPSEQvF2=	NHvodW9USU6JRWK=
NOS-1	M1qzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDSTWM2OD1yLkCwNlQzKM7:TR?=	M1\hWXNCVkeHUh?=
L-363	NWnD[4N4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTTTWM2OD1yLkCwNlg1KM7:TR?=	MULTRW5ITVJ?
RL95-2	NILlcItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;McGlEPTB;MD6wNFMzKM7:TR?=	MWTTRW5ITVJ?
BL-70	Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTBwMECzN\|ch\|ryP	NYfzbWh6W0GQR1XS
TGBC1TKB	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfUUnpKSzVyPUCuNFA{PzlizszN	MlvtV2FPT0WU
697	NEi2O3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorNTWM2OD1yLkCwOlM1KM7:TR?=	NUO2RmhDW0GQR1XS
RPMI-8226	NFHQUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2i2RmlEPTB;MD6wNFY2OSEQvF2=	MYfTRW5ITVJ?
BL-41	MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{[zbmlEPTB;MD6wNFY6PiEQvF2=	NFzifJNUSU6JRWK=
MRK-nu-1	NGS0TYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HsNWlEPTB;MD6wNFcxPyEQvF2=	MYjTRW5ITVJ?
EW-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjpdm1KSzVyPUCuNFA4PDlizszN	MlHSV2FPT0WU
EVSA-T	NI\SOpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoWwTWM2OD1yLkCwPFkzKM7:TR?=	NYXtW\|dKW0GQR1XS
HUTU-80	NIPmb\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEP1N\|JKSzVyPUCuNFA6OjlizszN	M4DkVnNCVkeHUh?=
VA-ES-BJ	NIrvbVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1H6VWlEPTB;MD6wNFk5PCEQvF2=	MXnTRW5ITVJ?
GCIY	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTBwMEGwNFch\|ryP	M4rzfHNCVkeHUh?=
ES6	Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkT2TWM2OD1yLkCxNFg{KM7:TR?=	NVvEV45rW0GQR1XS
NALM-6	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHCTWM2OD1yLkCxNVAzKM7:TR?=	NXrhSWFlW0GQR1XS
LB996-RCC	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3RZYJKSzVyPUCuNFEyOzdizszN	MUPTRW5ITVJ?
EW-16	NX;mT4p3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTBwMEGxPVIh\|ryP	NYfhVWViW0GQR1XS
KALS-1	MoXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTBwMEGxPVgh\|ryP	MXzTRW5ITVJ?
OPM-2	M33LUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrYTWM2OD1yLkCxNlkh\|ryP	NHfDOolUSU6JRWK=
KU812	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHHbXdKSzVyPUCuNFEzQTZizszN	M2DsW3NCVkeHUh?=
A4-Fuk	MnvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzqXoRkUUN3ME2wMlAyOzF7IN88US=>	NELPXWNUSU6JRWK=
KGN	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmflTWM2OD1yLkCxN\|U6KM7:TR?=	MVzTRW5ITVJ?
KS-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTBwMEGzPVIh\|ryP	MoPMV2FPT0WU
no-11	M1rLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLEdWxQUUN3ME2wMlAyOzl3IN88US=>	MV\TRW5ITVJ?
PSN1	Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTBwMEG0NFkh\|ryP	NE[2c2pUSU6JRWK=
SK-LMS-1	Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEf2SXBKSzVyPUCuNFE1OTNizszN	M4\IN3NCVkeHUh?=
LS-411N	NEXnb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTvO2dlUUN3ME2wMlAyPDN7IN88US=>	MnHQV2FPT0WU
HT-144	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LObmlEPTB;MD6wNVQ2OSEQvF2=	MnXOV2FPT0WU
ACN	NHPiXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLPTWM2OD1yLkCxOUDPxE1?	M4fxRXNCVkeHUh?=
RKO	NFzRO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\QTWM2OD1yLkCxOVM{KM7:TR?=	MWTTRW5ITVJ?
CMK	NEH5UGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPZeVdKSzVyPUCuNFE2PDNizszN	MYfTRW5ITVJ?
GB-1	NIfXS4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2foV2lEPTB;MD6wNVU2OyEQvF2=	MkPFV2FPT0WU
KE-37	MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mki2TWM2OD1yLkCxOVc{KM7:TR?=	NYP5TZp6W0GQR1XS
no-10	M3vxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHSSGdKSzVyPUCuNFE2QDRizszN	NUXrSXFlW0GQR1XS
MOLT-16	NV\lcmJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYKxd3RWUUN3ME2wMlAyPjJ{IN88US=>	NFXscYpUSU6JRWK=
HEL	MmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXuTWM2OD1yLkCxOlQh\|ryP	MXXTRW5ITVJ?
NCI-H1355	M2D4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TDOWlEPTB;MD6wNVY1PiEQvF2=	M3H4R3NCVkeHUh?=
IST-MEL1	M3PZ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTBwMEG3O\|Qh\|ryP	MUfTRW5ITVJ?
MHH-PREB-1	MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjRTWM2OD1yLkCxPFE5KM7:TR?=	NH;GOJJUSU6JRWK=
ES8	M1XaNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTBwMEG4OFQh\|ryP	MoHIV2FPT0WU
LC-2-ad	M1q3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIS0UGFKSzVyPUCuNFIyOzdizszN	MmLGV2FPT0WU
LAMA-84	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXtVGxKSzVyPUCuNFIyPjdizszN	M{LNNnNCVkeHUh?=
BV-173	NYThXm1yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGC5T3ZKSzVyPUCuNFIzODNizszN	MYHTRW5ITVJ?
SW872	MmnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoD5TWM2OD1yLkCyNlQ4KM7:TR?=	NET3TGlUSU6JRWK=
SK-UT-1	MoD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkCxTWM2OD1yLkCyNlYyKM7:TR?=	M2\FRnNCVkeHUh?=
OS-RC-2	NXvhRVBtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrlVFhKSzVyPUCuNFI{OjNizszN	M{fwfXNCVkeHUh?=
NCI-H747	NFez[\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn25TWM2OD1yLkCyN\|Mh\|ryP	MnrhV2FPT0WU
MZ2-MEL	M4rhWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHSbpJKSzVyPUCuNFI{OzdizszN	NH3aUVRUSU6JRWK=
TE-11	NXPMNolNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{f6SmlEPTB;MD6wNlM4OiEQvF2=	MWfTRW5ITVJ?
KURAMOCHI	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLIS\|M6UUN3ME2wMlAzPDF2IN88US=>	NWL0SnZGW0GQR1XS
HD-MY-Z	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTBwMEK0NlYh\|ryP	NWLmOlJIW0GQR1XS
GI-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3njSGlEPTB;MD6wNlQ3QSEQvF2=	NGjhWm5USU6JRWK=
LB1047-RCC	M4\xdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTBwMEK0PFgh\|ryP	Mnf4V2FPT0WU
TE-12	NUG0W49pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlK2TWM2OD1yLkCyOVUh\|ryP	MmLvV2FPT0WU
MZ7-mel	NWmybZdbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLIRo9FUUN3ME2wMlAzPjB7IN88US=>	NXm3fZRPW0GQR1XS
MMAC-SF	M1vwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTBwMEK2N\|Mh\|ryP	MnXWV2FPT0WU
A101D	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLPTWM2OD1yLkCyOlUh\|ryP	MmqzV2FPT0WU
GR-ST	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwMEK2OVUh\|ryP	NY\UWnVJW0GQR1XS
MC116	MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXO1VYI4UUN3ME2wMlAzPjhizszN	M3vpUnNCVkeHUh?=
Ramos-2G6-4C10	M1jjXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkezTWM2OD1yLkCyO\|Uh\|ryP	NVnDXW5wW0GQR1XS
ATN-1	NGLMZZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{Lq[WlEPTB;MD6wNlc5QSEQvF2=	NYfTfVJIW0GQR1XS
MFH-ino	NXrRU4g1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFuxT3VKSzVyPUCuNFI5OTJizszN	NEKzVFJUSU6JRWK=
DEL	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LSeWlEPTB;MD6wNlgyPSEQvF2=	NIO1b\|dUSU6JRWK=
OCI-AML2	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvTR\|hKSzVyPUCuNFI5PzFizszN	MUnTRW5ITVJ?
LXF-289	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTBwMEK4O\|Ih\|ryP	NHTpdW5USU6JRWK=
IA-LM	Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHoUmFKSzVyPUCuNFI6OTdizszN	MlXkV2FPT0WU
EoL-1-cell	M4TDc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\iO2lEPTB;MD6wNlk6PiEQvF2=	NGDHTIpUSU6JRWK=
OVCAR-4	M2HkRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\PbpRJUUN3ME2wMlA{ODl2IN88US=>	MVjTRW5ITVJ?
ES1	NGi0O\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\LTWM2OD1yLkCzNFk4KM7:TR?=	M4HQVnNCVkeHUh?=
CESS	NGPBOpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3xem5EUUN3ME2wMlA{ODl7IN88US=>	M175NHNCVkeHUh?=
GAK	NY[zOpVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfCVYNKSzVyPUCuNFMyQDZizszN	NWPaXWFXW0GQR1XS
NTERA-S-cl-D1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDKOWY{UUN3ME2wMlA{OjJ4IN88US=>	M4njZnNCVkeHUh?=
TE-10	M{DpNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnpNIt5UUN3ME2wMlA{OzFzIN88US=>	M4TsenNCVkeHUh?=
CCRF-CEM	NF3PNZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHaTWM2OD1yLkCzN\|cyKM7:TR?=	NInybYRUSU6JRWK=
NMC-G1	NX;4V4ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3CTWM2OD1yLkCzOFQ5KM7:TR?=	MX7TRW5ITVJ?
HOP-62	MnfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\3O4loUUN3ME2wMlA{PTV4IN88US=>	MX\TRW5ITVJ?
SH-4	NXTzUI9zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI[xephKSzVyPUCuNFM2QDJizszN	NU\ONZAzW0GQR1XS
NCI-H1648	NWDwd49IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLJTWM2OD1yLkCzOlIzKM7:TR?=	MmW4V2FPT0WU
EB-3	NFHvcY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;YO5NKSzVyPUCuNFM3PDNizszN	NVHJTlhYW0GQR1XS
BB65-RCC	NXvVN\|h6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;YVI9sUUN3ME2wMlA{PjlzIN88US=>	MYDTRW5ITVJ?
BE-13	NFjmW21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHITWM2OD1yLkCzO\|U6KM7:TR?=	M2\GdXNCVkeHUh?=
CP67-MEL	MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jXbmlEPTB;MD6wN\|c2QSEQvF2=	MlrBV2FPT0WU
SW954	Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPpTWM2OD1yLkCzO\|kh\|ryP	NIjPUotUSU6JRWK=
TE-5	NEjqUm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DhOGlEPTB;MD6wN\|g2PCEQvF2=	M4D5dHNCVkeHUh?=
HCE-4	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7zTWM2OD1yLkCzPFU2KM7:TR?=	MVTTRW5ITVJ?
LC-1F	NH:yN\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPmNWpKSzVyPUCuNFM6QDlizszN	NUPscIp3W0GQR1XS
TK10	NIHGS2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEG5UoFKSzVyPUCuNFQxOTlizszN	M{\pTnNCVkeHUh?=
SJSA-1	NYXT[no4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITj[VlKSzVyPUCuNFQyQDhizszN	MXrTRW5ITVJ?
Daudi	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTBwMESyNlUh\|ryP	MXPTRW5ITVJ?
SW982	M4PlUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTiSGRJUUN3ME2wMlA1OjR4IN88US=>	MUPTRW5ITVJ?
SF126	MkjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rHVWlEPTB;MD6wOFM3OSEQvF2=	M{fGenNCVkeHUh?=
TE-15	M1mxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{T6WGlEPTB;MD6wOFQ{PSEQvF2=	MUXTRW5ITVJ?
COLO-684	M4Lxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX:xSllbUUN3ME2wMlA1PTZzIN88US=>	NXHzcGpnW0GQR1XS
8-MG-BA	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPUTWM2OD1yLkC0OlI6KM7:TR?=	M1vyWHNCVkeHUh?=
NB13	M4\Be2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\T[2RKSzVyPUCuNFQ4PzZizszN	NHH0OIxUSU6JRWK=
HCC1599	NHK1dmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTBwMES4O\|kh\|ryP	NYXOb5FkW0GQR1XS
SK-PN-DW	MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mne2TWM2OD1yLkC0PVQ6KM7:TR?=	NWHGWo1jW0GQR1XS
ALL-PO	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\MVYlKSzVyPUCuNFQ6PTZizszN	MXLTRW5ITVJ?
NB6	NYX3fZV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXy5R3RTUUN3ME2wMlA2OjdzIN88US=>	MkLhV2FPT0WU
IST-SL2	NITHd4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHj5Z3pKSzVyPUCuNFU{PjJizszN	MUDTRW5ITVJ?
BB30-HNC	M2jrRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYT6XoJGUUN3ME2wMlA2PzNizszN	MVPTRW5ITVJ?
SW962	Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTBwMEW3OlMh\|ryP	NFexe\|lUSU6JRWK=
TGBC24TKB	NVnSSFFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzxdnVWUUN3ME2wMlA2Pzl7IN88US=>	MmS3V2FPT0WU
KINGS-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\pVZZKSzVyPUCuNFU5ODNizszN	MV7TRW5ITVJ?
HC-1	NHPNfHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HwUWlEPTB;MD6wOVgzPyEQvF2=	Mm\oV2FPT0WU
RS4-11	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PaPGlEPTB;MD6wOVk{QCEQvF2=	NV;RO481W0GQR1XS
LS-123	MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPTPWNKSzVyPUCuNFU6PDJizszN	NWXjdW9mW0GQR1XS
A3-KAW	M1nWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XKSWlEPTB;MD6wOlIzPSEQvF2=	NYXTS5RMW0GQR1XS
SNB75	NIHueVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFP0fmNKSzVyPUCuNFY{PDFizszN	MYrTRW5ITVJ?
SR	NHPVUJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTBwME[zO\|Qh\|ryP	Ml7kV2FPT0WU
LOUCY	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrlTWM2OD1yLkC2N\|k1KM7:TR?=	MoG1V2FPT0WU
K5	M37xSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwME[0NFMh\|ryP	MXLTRW5ITVJ?
Becker	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;2R2lEPTB;MD6wOlQzKM7:TR?=	MV\TRW5ITVJ?
CTV-1	MnG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\tcoNyUUN3ME2wMlA3PTR6IN88US=>	Mkf4V2FPT0WU
KLE	NX3CUIVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTBwME[1PFQh\|ryP	MoC1V2FPT0WU
MZ1-PC	MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXNPZBrUUN3ME2wMlA3PTl6IN88US=>	NVnXV4tNW0GQR1XS
MOLT-4	M3LxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmqyTWM2OD1yLkC2OlA2KM7:TR?=	NVnCbFl7W0GQR1XS
MLMA	MnnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTBwME[3PEDPxE1?	M4nt[HNCVkeHUh?=
A388	NUjnbmJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUT4T45OUUN3ME2wMlA3QDl\|IN88US=>	MYrTRW5ITVJ?
MV-4-11	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwME[5PVUh\|ryP	MnzsV2FPT0WU
DSH1	M3Px[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfqPG1KSzVyPUCuNFcyPzNizszN	MWLTRW5ITVJ?
MONO-MAC-6	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\XXnJxUUN3ME2wMlA4OjF{IN88US=>	MWPTRW5ITVJ?
ARH-77	NFXXUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPTZno6UUN3ME2wMlA4Ojd6IN88US=>	NHjDdWNUSU6JRWK=
LB771-HNC	M2CyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmexTWM2OD1yLkC3OVQ6KM7:TR?=	NIPy[ZBUSU6JRWK=
PF-382	NIfmZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3q2eGlEPTB;MD6wO\|U3QSEQvF2=	MX3TRW5ITVJ?
KM12	NX7KV5UzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HtXmlEPTB;MD6wO\|Y1KM7:TR?=	MmT5V2FPT0WU
HAL-01	M{n2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTBwMEe2OVgh\|ryP	MY\TRW5ITVJ?
RPMI-8402	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\rWFcyUUN3ME2wMlA4Pzh7IN88US=>	NGm2[Y1USU6JRWK=
OMC-1	M1rS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHzTWM2OD1yLkC3PFA1KM7:TR?=	NEDZcFJUSU6JRWK=
HT	MoLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\B[JpKSzVyPUCuNFgh\|ryP	NFHJXW9USU6JRWK=
QIMR-WIL	NWLyUo95T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1mxVmlEPTB;MD6wPFA2PSEQvF2=	NInUcnFUSU6JRWK=
KNS-42	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4O4VGlEPTB;MD6wPFIxOyEQvF2=	NYfGUlVVW0GQR1XS
BC-3	NUXSR4lsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\iTWM2OD1yLkC4NlA1KM7:TR?=	MmfnV2FPT0WU
ES4	M3nDOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEKzWIZKSzVyPUCuNFgzQTZizszN	M{DrZXNCVkeHUh?=
NCI-H23	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELyVWpKSzVyPUCuNFg1PCEQvF2=	NH\lN\|ZUSU6JRWK=
LB2518-MEL	NHP2T\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TPZ2lEPTB;MD6wPFY6PiEQvF2=	NUDvToZ7W0GQR1XS
LC4-1	NF3PSXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTBwMEi3N\|gh\|ryP	NUTxdVZ{W0GQR1XS
SIG-M5	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF[zZpJKSzVyPUCuNFg6ODRizszN	MXvTRW5ITVJ?
LP-1	NVr4PFdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPXfJJGUUN3ME2wMlA5QTN6IN88US=>	MkfHV2FPT0WU
TE-8	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;XTWM2OD1yLkC5NFE3KM7:TR?=	MlSzV2FPT0WU
K-562	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGqzbXRKSzVyPUCuNFkyOiEQvF2=	MYjTRW5ITVJ?
J-RT3-T3-5	NUDvTnZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TBSWlEPTB;MD6wPVE2OyEQvF2=	MVzTRW5ITVJ?
DU-4475	M33E[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTBwMEmxOlUh\|ryP	MnjvV2FPT0WU
RXF393	NEHsZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTyWW1KSzVyPUCuNFk1PjJizszN	NIrmNYZUSU6JRWK=
NB5	M1q0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTBwMEm2NlUh\|ryP	NY\mU\|BzW0GQR1XS
A704	NXfrRXNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\hSm1KSzVyPUCuNFk4PDFizszN	NUjacY95W0GQR1XS
SF268	MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\STWM2OD1yLkC5PFI2KM7:TR?=	NHS3V5hUSU6JRWK=
UACC-257	MmK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;rNFlKSzVyPUCuNFk5OzNizszN	MlnlV2FPT0WU
L-428	NXjCR3BsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonZTWM2OD1yLkGwN\|Ih\|ryP	NVjofYNjW0GQR1XS
ST486	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HQdmlEPTB;MD6xNFYxPiEQvF2=	MXLTRW5ITVJ?
SK-MM-2	NWn1U3VlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrBTFhKSzVyPUCuNVA4ODlizszN	NIfnOFJUSU6JRWK=
COR-L279	M1vRTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLXSGhmUUN3ME2wMlExQDN{IN88US=>	NWfxR21pW0GQR1XS
JiyoyeP-2003	MmTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLtTWM2OD1yLkGwPFQ{KM7:TR?=	NUnZbWc3W0GQR1XS
GT3TKB	NGHZRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXITWM2OD1yLkGwPVE5KM7:TR?=	M2H0e3NCVkeHUh?=
HCE-T	MoG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nje2lEPTB;MD6xNFk1KM7:TR?=	M{KxOXNCVkeHUh?=
SBC-1	NXjxPFdmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{eybGlEPTB;MD6xNVEyQSEQvF2=	NV\od\|ZNW0GQR1XS
KNS-81-FD	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;aTWM2OD1yLkGxNlc{KM7:TR?=	MYjTRW5ITVJ?
NCI-H2126	M1zIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzs[4RKSzVyPUCuNVE{QTRizszN	Ml\jV2FPT0WU
EM-2	M160Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTBwMUG1Nlkh\|ryP	NYjmWWVYW0GQR1XS
JAR	NE\YNlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTBwMUG1PVgh\|ryP	NUDkZ2xpW0GQR1XS
NB17	MoizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTBwMUG2OVIh\|ryP	M{jUWXNCVkeHUh?=
LB647-SCLC	Mlr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHntTWRKSzVyPUCuNVE4ODVizszN	MYXTRW5ITVJ?
CAL-148	MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkX3TWM2OD1yLkGxPEDPxE1?	NHfjZWVUSU6JRWK=
K052	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLaTWM2OD1yLkGxPFUyKM7:TR?=	MXfTRW5ITVJ?
KARPAS-299	NF\tPFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\BS\|NDUUN3ME2wMlEzOjN\|IN88US=>	Mo[0V2FPT0WU
KARPAS-422	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nON2lEPTB;MD6xNlQ{OiEQvF2=	NWnmNmJLW0GQR1XS
LOXIMVI	NWKzd5VET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXySGVKSzVyPUCuNVI2OTVizszN	M{XKXXNCVkeHUh?=
SCC-3	NUjSWZJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXVNIlKSzVyPUCuNVI5PTFizszN	MXPTRW5ITVJ?
LU-139	M3PHbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\ucWtuUUN3ME2wMlEzQTd3IN88US=>	NEHCVHpUSU6JRWK=
COLO-320-HSR	NX\OPZBpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTBwMUOwPFYh\|ryP	MmrOV2FPT0WU
ONS-76	NHLpcHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUi4dIFwUUN3ME2wMlE{OTNizszN	MWjTRW5ITVJ?
U-266	M{DYO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LZPWlEPTB;MD6xN\|I1PSEQvF2=	MX\TRW5ITVJ?
HH	M4qy[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\aXGpKSzVyPUCuNVM2OzVizszN	NILteJpUSU6JRWK=
BB49-HNC	MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\FNmxCUUN3ME2wMlE{PTh5IN88US=>	NHzoVFlUSU6JRWK=
NCI-SNU-5	NYjoNI9bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHaTWM2OD1yLkGzOVk3KM7:TR?=	MXfTRW5ITVJ?
C2BBe1	NEjyZo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHj0cGlKSzVyPUCuNVM4PDZizszN	NUPIPGlWW0GQR1XS
ML-2	MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrFWmtiUUN3ME2wMlE{QTV\|IN88US=>	NVO4N3JXW0GQR1XS
SCH	NUTQWHNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTBwMUO5O\|Qh\|ryP	NFK5UYRUSU6JRWK=
NCI-H82	M3rDTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jGNWlEPTB;MD6xOFExPCEQvF2=	M{XndXNCVkeHUh?=
MDA-MB-134-VI	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwMUSyOVIh\|ryP	MXPTRW5ITVJ?
SK-N-DZ	M2nROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXPS\|ZQUUN3ME2wMlE1PzF7IN88US=>	NX20OnNTW0GQR1XS
HL-60	NEDUSmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rZWWlEPTB;MD6xOFkzKM7:TR?=	MkO5V2FPT0WU
LB373-MEL-D	NUTJfYhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFf6RphKSzVyPUCuNVU2OzlizszN	NIHpT2xUSU6JRWK=
LB831-BLC	Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfSTWM2OD1yLkG2NFc3KM7:TR?=	MonDV2FPT0WU
SK-NEP-1	MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYe3Z2xDUUN3ME2wMlE3OTBzIN88US=>	M4PDS3NCVkeHUh?=
IMR-5	Mn:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHWdYNZUUN3ME2wMlE3PDh\|IN88US=>	NHj3S2tUSU6JRWK=
Calu-6	M2D4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrkclJKSzVyPUCuNVY2OzdizszN	MXLTRW5ITVJ?
NCI-H1882	NUL2V5JkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXr4O2pGUUN3ME2wMlE3PzJ6IN88US=>	MlzzV2FPT0WU
NCI-H446	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTjTWM2OD1yLkG2PFkyKM7:TR?=	M2HU[XNCVkeHUh?=
GI-ME-N	M4DYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlj3TWM2OD1yLkG4NFIh\|ryP	MW\TRW5ITVJ?
MPP-89	NXfScpNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrvWXVKSzVyPUCuNVgyOjFizszN	M3PlVHNCVkeHUh?=
CGTH-W-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTBwMUi0N\|Yh\|ryP	MXTTRW5ITVJ?
MEG-01	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHP3XFFKSzVyPUCuNVg3OjhizszN	Ml;tV2FPT0WU
NCI-H748	M3TKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTBwMUi5NVEh\|ryP	MYrTRW5ITVJ?
COLO-829	NXK0ZVNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLPTWM2OD1yLkKwOlc{KM7:TR?=	NWfsfmpyW0GQR1XS
GOTO	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\sbIFKSzVyPUCuNlA4OyEQvF2=	NUPnWVNPW0GQR1XS
EW-3	MmHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkj6TWM2OD1yLkKxO\|E5KM7:TR?=	M4TReXNCVkeHUh?=
KY821	NEDhOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTSN5dKSzVyPUCuNlIxPDVizszN	NIP2WIZUSU6JRWK=
CTB-1	M1OzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3y2PGlEPTB;MD6yNlIzQCEQvF2=	MUDTRW5ITVJ?
TALL-1	M3X3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHZTWM2OD1yLkKyPVIyKM7:TR?=	NFrlTFBUSU6JRWK=
NCI-H209	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\0UFBKSzVyPUCuNlI6PjJizszN	MWPTRW5ITVJ?
IST-MES1	NGPKSHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mkm4TWM2OD1yLkKzOVEh\|ryP	MlzOV2FPT0WU
DMS-114	Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnyTWM2OD1yLkKzPVk{KM7:TR?=	Mn7wV2FPT0WU
SNU-C2B	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrlR4ljUUN3ME2wMlI1OzF4IN88US=>	M1TacHNCVkeHUh?=
DG-75	NI\vS2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnnV2dFUUN3ME2wMlI3OTl3IN88US=>	MULTRW5ITVJ?
D-336MG	MnezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3n0ZWlEPTB;MD6yOlU2PyEQvF2=	NUftZmJOW0GQR1XS
KMOE-2	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\FNmM1UUN3ME2wMlI4PTN6IN88US=>	NYXJSXN1W0GQR1XS
NB1	MnzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2njcWlEPTB;MD6yO\|kzPiEQvF2=	M122NnNCVkeHUh?=
RH-1	MnTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrHenVKSzVyPUCuNlc6QDlizszN	NGPOPZZUSU6JRWK=
TE-1	NUDKUHZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTBwMki0O\|kh\|ryP	NFrtb4hUSU6JRWK=
RPMI-6666	MoWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HGRWlEPTB;MD6yPFg1KM7:TR?=	M{LEVXNCVkeHUh?=
TE-9	M4fhT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LJNmlEPTB;MD6yPFk5PSEQvF2=	Mon2V2FPT0WU
BT-474	M3jnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{PiTWlEPTB;MD6yPVM{PCEQvF2=	MXTTRW5ITVJ?
COLO-668	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fZSGlEPTB;MD6yPVQzQSEQvF2=	M1zCUHNCVkeHUh?=
NCI-H1581	MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\KTWM2OD1yLkK5Olg6KM7:TR?=	M2T0T3NCVkeHUh?=
MN-60	NUC5OpJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\Jc5JKSzVyPUCuNlk6ODVizszN	NWr2T\|J6W0GQR1XS
L-540	NFHmWIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTxTWM2OD1yLkOwNFgyKM7:TR?=	NFjHVZFUSU6JRWK=
MOLT-13	Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XZT2lEPTB;MD6zNFE5OyEQvF2=	NXHDV3ZiW0GQR1XS
NCI-SNU-16	M33ORWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIn0R2tKSzVyPUCuN\|AzODVizszN	M4nQUHNCVkeHUh?=
NCI-H64	NVHDWXBvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTBwM{CzN\|Eh\|ryP	M2i5O3NCVkeHUh?=
CP66-MEL	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXGTWM2OD1yLkOxOFE2KM7:TR?=	NW\6RpNRW0GQR1XS
NB69	M3m0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPGd5BKSzVyPUCuN\|IyQDhizszN	M2DnOnNCVkeHUh?=
NCI-H2196	NXn3[5VLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrZRWtFUUN3ME2wMlM{ODN4IN88US=>	MXjTRW5ITVJ?
MHH-CALL-2	NVTDV\|BiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTBwM{O0Olgh\|ryP	MUPTRW5ITVJ?
HCC2157	M2\uXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlywTWM2OD1yLkOzPVU1KM7:TR?=	NH3pV2tUSU6JRWK=
LS-1034	NIK5dpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTBwM{[zPFgh\|ryP	NGrDcIxUSU6JRWK=
BOKU	MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYfPXVI1UUN3ME2wMlM4OTl7IN88US=>	NEfON2VUSU6JRWK=
GDM-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTBwM{eyN\|Qh\|ryP	NHvjUlRUSU6JRWK=
TGW	MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwM{e0OVMh\|ryP	MkTQV2FPT0WU
SNU-C1	Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTBwM{iyNVUh\|ryP	NV\0bm02W0GQR1XS
LS-513	NY\xOIR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDpOHlrUUN3ME2wMlM6ODdzIN88US=>	NVzPWoRPW0GQR1XS
NOMO-1	MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rTZmlEPTB;MD6zPVk4OSEQvF2=	MVrTRW5ITVJ?
MS-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\HfGV1UUN3ME2wMlQxOTd5IN88US=>	NUXPNlF5W0GQR1XS
EKVX	NGXmOnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzuTWM2OD1yLkS0OFYyKM7:TR?=	MYfTRW5ITVJ?
SK-MEL-2	NG\pTHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LIWWlEPTB;MD60OlQh\|ryP	MXPTRW5ITVJ?
HCC1187	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3jOINKSzVyPUCuOFY4PjhizszN	M2jzN3NCVkeHUh?=
HCC2218	M2W1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jKbGlEPTB;MD60O\|IzPyEQvF2=	NHHTdlZUSU6JRWK=
NCI-H187	NXOwSYM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTNcIdVUUN3ME2wMlQ4QDRizszN	M{LLOHNCVkeHUh?=
DB	NX\3bJVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DuOmlEPTB;MD61NFA2PSEQvF2=	MkTTV2FPT0WU
NCI-H69	M2rF[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrGbZhKSzVyPUCuOVAzPDdizszN	NFvGOZdUSU6JRWK=
NCI-H1694	MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfsTWM2OD1yLkWwOlk4KM7:TR?=	MoDLV2FPT0WU
CA46	NUC1VYJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTBwNUC5NVch\|ryP	NEH0eXlUSU6JRWK=
EHEB	MnPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrUVHZKSzVyPUCuOVEyQTNizszN	NV3tVFdZW0GQR1XS
NCCIT	M4DydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTBwNUSzNlEh\|ryP	NXTTRW9VW0GQR1XS
NCI-H720	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrsT5lqUUN3ME2wMlU1QTZ{IN88US=>	M3X5NnNCVkeHUh?=
LU-134-A	M3:2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPNb2ZVUUN3ME2wMlU2Ojl4IN88US=>	M2rEXnNCVkeHUh?=
MC-CAR	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWHIU41sUUN3ME2wMlU2PDNzIN88US=>	Mn25V2FPT0WU
NEC8	NIHQeGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGj4ZYtKSzVyPUCuOVYyPzJizszN	M2HTU3NCVkeHUh?=
NCI-H524	NXP3b3hLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTBwNUi3OFgh\|ryP	NGTpfVNUSU6JRWK=
NCI-H1963	M1fMUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vQbGlEPTB;MD62NlU5KM7:TR?=	MlTWV2FPT0WU
SU-DHL-1	Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPTUYZOUUN3ME2wMlY1PTJ4IN88US=>	NGHNOHhUSU6JRWK=
NCI-H1522	MmO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3ToWmlEPTB;MD62OFg5OyEQvF2=	NHfQ[nhUSU6JRWK=
NCI-H1155	NXjXcnRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\3TmJbUUN3ME2wMlY2OzVizszN	M3HOZnNCVkeHUh?=
D-263MG	NF\UbGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrReYhKSzVyPUCuOlYyODFizszN	M4XtdHNCVkeHUh?=
TE-6	NYfTOYp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIn1eWhKSzVyPUCuOlgyODRizszN	NVqxcFA1W0GQR1XS
NCI-H1417	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rtOGlEPTB;MD62PVcyOSEQvF2=	MmnwV2FPT0WU
NCI-H510A	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPCTWM2OD1yLke3NlM3KM7:TR?=	NXO1fopjW0GQR1XS
KARPAS-45	NFG4cnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHG3fYlKSzVyPUCuO\|gzOzVizszN	M4DBWXNCVkeHUh?=
IST-SL1	NXju[nhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzSXXFKSzVyPUCuPFU5OjVizszN	NXrNO3ZuW0GQR1XS
COLO-824	Mn\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLsUJhKSzVyPUCuPFc5OzVizszN	M3nnfXNCVkeHUh?=
NCI-H526	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjoTXBKSzVyPUCuPVA6PThizszN	NYDKTWp4W0GQR1XS
NCI-H719	Mm\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjiPXJCUUN3ME2wMlk3PjV5IN88US=>	MYDTRW5ITVJ?
SF539	NXLES4NqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PUTWlEPTB;MD65PFM6PiEQvF2=	M4C1cnNCVkeHUh?=
NKM-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTBwOUi2OlMh\|ryP	MXHTRW5ITVJ?
A253	MoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFL0eGxKSzVyPUCuPVg5QDVizszN	NH7qcHhUSU6JRWK=
TE-441-T	NXnHN3NpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTFwMESzOUDPxE1?	MVLTRW5ITVJ?
COR-L88	MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWKxZm14UUN3ME2xMlEyOzV2IN88US=>	MWnTRW5ITVJ?
CPC-N	Mlv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWT1ZVU{UUN3ME2xMlE2QDh6IN88US=>	NGjwb2VUSU6JRWK=
NCI-H2107	NFTGfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rNWGlEPTB;MT6xO\|I3OSEQvF2=	MkixV2FPT0WU
ECC4	M3nIUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjiTWM2OD1zLkG4Olk{KM7:TR?=	MYPTRW5ITVJ?
NCI-H2141	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zPWWlEPTB;MT6xPVI6QSEQvF2=	NX7LTZFSW0GQR1XS
NCI-H1770	M{PUUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LFU2lEPTB;MT6zNlkzQCEQvF2=	Mo\EV2FPT0WU
NCI-SNU-1	MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;lSHNKSzVyPUGuN\|MxPCEQvF2=	MVzTRW5ITVJ?
LU-165	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4WzR2lEPTB;MT60OVQ3PyEQvF2=	M1T6cnNCVkeHUh?=
Raji	M1\VUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHqWGFKSzVyPUGuOFczPTlizszN	MX7TRW5ITVJ?
EW-24	M1j5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnmTWM2OD1zLkW0OlE6KM7:TR?=	NWPROWc4W0GQR1XS
KP-N-RT-BM-1	NVzRWHdIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjYXZNKSzVyPUGuOVY2PTFizszN	NYTMc41RW0GQR1XS
SK-MEL-1	M4fsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTFwNkS4O\|ch\|ryP	M4\keXNCVkeHUh?=
SCLC-21H	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLiblJFUUN3ME2xMlY3PjVzIN88US=>	NVK5OJhkW0GQR1XS
SIMA	Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTFwNkiyN\|Mh\|ryP	MX3TRW5ITVJ?
NCI-H1304	NGj1c2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnjTWM2OD1zLkewO\|Y2KM7:TR?=	MmLHV2FPT0WU
REH	NHnKOJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTFwN{GwO\|gh\|ryP	M4Toe3NCVkeHUh?=
KP-N-YS	M1HvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;QW2lEPTB;MT65N\|U2OSEQvF2=	NF30WHhUSU6JRWK=
DMS-153	NYDlcpVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHYTWM2OD1zLkm3OVkh\|ryP	MVLTRW5ITVJ?
NB10	NGLWUpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTJwMkC4O\|gh\|ryP	NH7JNIdUSU6JRWK=
NCI-H345	M3TqWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTJwNkG5NFUh\|ryP	MWTTRW5ITVJ?
SK-N-FI	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrHe3lvUUN3ME2yMlc2OzhzIN88US=>	M2DwNXNCVkeHUh?=
NCI-H1092	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{L3WGlEPTB;Mj65OVM6PCEQvF2=	NGK3RYZUSU6JRWK=
KM-H2	MoXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIm0TopKSzVyPUOuOlU{QTZizszN	NHfvc3RUSU6JRWK=
KG-1	MnHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfrTWM2OD1\|LkexOlg5KM7:TR?=	MojHV2FPT0WU
D-283MED	MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3QPFJKSzVyPUOuO\|U5PyEQvF2=	NEXhcFZUSU6JRWK=
LU-65	NVrEPYtxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTrTWM2OD12LkGxOFg2KM7:TR?=	NVjEVGIxW0GQR1XS
MSTO-211H	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLMTWM2OD12LkG4PFk5KM7:TR?=	MkDjV2FPT0WU
NCI-H2081	NW[3[oxiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGftUHJKSzVyPUSuNlkyPzRizszN	M1joOXNCVkeHUh?=
D-247MG	M{jwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDUfnpKSzVyPUSuOFMyQTFizszN	NWTi[pI{W0GQR1XS
P31-FUJ	NFXnc\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTpR\|EyUUN3ME20MlQ2ODF7IN88US=>	NXXGS5dMW0GQR1XS
DMS-79	NFjxSW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2D2SWlEPTB;ND65N\|E5OyEQvF2=	NX7Wc41RW0GQR1XS
KASUMI-1	NHLpZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvDOopKSzVyPUSuPVc2ODlizszN	NEWyZ\|ZUSU6JRWK=
JVM-3	M4nMc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTVwMkWwNVQh\|ryP	NVjwenBJW0GQR1XS
LAN-6	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTVwNUG3N\|Yh\|ryP	NEfO[IRUSU6JRWK=
DJM-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHy5eI5KSzVyPUWuOVYxOjlizszN	NEP6[4FUSU6JRWK=
JVM-2	NWG2ZZJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTVwNkewPVIh\|ryP	MnvNV2FPT0WU
U-87-MG	NXf6dnJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYL3b5IxUUN3ME21Mlg6QTZ2IN88US=>	MWTTRW5ITVJ?
SHP-77	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3sNnRKSzVyPUWuPVQ6OjhizszN	NYHm[W1nW0GQR1XS
RPMI-8866	NX;0Z2RkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnveo5nUUN3ME22MlI4ODF\|IN88US=>	M1rvUXNCVkeHUh?=
ES7	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fuWmlEPTB;Nj6zPVkzPCEQvF2=	MlzkV2FPT0WU
WSU-NHL	M1;vNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzHe3VKSzVyPU[uOVE3ODlizszN	MUjTRW5ITVJ?
CAS-1	MmXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlOzTWM2OD15LkC5O\|Q6KM7:TR?=	MnHIV2FPT0WU
MHH-NB-11	NHe5WIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;pTWM2OD16LkKzNVUzKM7:TR?=	M3W2N3NCVkeHUh?=
ES5	NWfWWolsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTlwNUKyPFYh\|ryP	NVj3UYRtW0GQR1XS
HDLM-2	MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHhT\|l6UUN3ME25Mlk2QTB{IN88US=>	MUHTRW5ITVJ?
NCI-H2171	NXq3fIRFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTFyLkW5Nlch\|ryP	NX\3emhQW0GQR1XS
LNCaP-Clone-FGC	NE\HZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\MTWM2OD1zMT6zO\|E5KM7:TR?=	M4qxWHNCVkeHUh?=
NCI-H1395	NYPhb4xUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LmcmlEPTB;MUKuNlY6QSEQvF2=	M3qxdXNCVkeHUh?=
NCI-H1436	M4\CeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTF\|LkOxPVUh\|ryP	MoPMV2FPT0WU
RCC10RGB	NXvhd5A4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7rTWM2OD1zMz6zNlIyKM7:TR?=	NUL6ZZpbW0GQR1XS
SW684	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\ETWM2OD1zMz65O\|k4KM7:TR?=	M2PPb3NCVkeHUh?=
NCI-H1650	NHTqOVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmeyTWM2OD1zNT6wOFQ4KM7:TR?=	MXPTRW5ITVJ?
EW-13	MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTF3LkKwNlEh\|ryP	M1nPUHNCVkeHUh?=
EC-GI-10	Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYi5SnVsUUN3ME2xOU45PjR2IN88US=>	NWjZR\|RwW0GQR1XS
CHP-126	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITVdo9KSzVyPUG3MlE6OThizszN	M2LlUXNCVkeHUh?=
NCI-H226	Mm\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nLcGlEPTB;MUiuNFQxOyEQvF2=	MmXkV2FPT0WU
NCI-H1838	MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrYTWM2OD1{MD6xPFQ5KM7:TR?=	NF71XGtUSU6JRWK=
EW-11	M3HTWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nWWmlEPTB;MkSuNlcyQCEQvF2=	MULTRW5ITVJ?
EB2	NXP6UoNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnpSppHUUN3ME2zNU42OzF6IN88US=>	M33GTHNCVkeHUh?=
D-502MG	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPj[GRKSzVyPUSzMlkzOjlizszN	M1;w[nNCVkeHUh?=
U-698-M	M176Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLme5hJUUN3ME20PE45PjdzIN88US=>	NEmyN3pUSU6JRWK=
ES3	MknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTCWZlKSzVyPUS5MlM5QTNizszN	Moj1V2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	ATF4 / p-S6K(T389) / S6K / p-eIF2α(S51) / eIF2α / 4EBP1 / eIF3b; PubMed: 28494858 Cell Rep 4E-BPs are required for mTOR control of ATF4. 4E-BP1/2 wild-type (WT), double knockout (DKO), or DKO MEFs stably expressing 4ebp1 (DKO + 4ebp1) were treated with vehicle (DMSO) or 250 nM Torin 1 for 4 hr. Cell extracts were analyzed by immunoblotting for the indicated proteins. LC3 / p62 / PARP / pAKT(S473) / p4EBP1(S65) / pS6K1(T389) / pS6(S235/236); PubMed: 24126619 Int J Oncol Cells were treated with increasing doses of the mTOR inhibitors, torin 1 (A) and rapamycin (B), in RPMI-1640 containing 10% FBS for 2 days. LC3 processing, p62 accumulation, PARP cleavage, AKT phosphorylation and mTOR pathway activity (indicated by phosphorylation of 4E-BP, S6K1 and S6) were analyzed by western blotting of total cell lysates. GAPDH was the control for protein loading. p-mTOR(S2481) / mTOR / rictor / Sin1 / p-Akt S473 / p-Akt T450 / p-Akt T308 / p-S6K1 T389 / S6K1; PubMed: 21965657 J Biol Chem mTOR kinase activity controls abundance of SIN1. MDA-MB-435 cells were incubated with specific mTOR inhibitor (0.5 μm TORIN) for 24 or 48 h and analyzed. Vinculin / p-S6; PubMed: 28757207 Mol Cell A375 cells were treated with Torin1 for 48 h and localization of proteins was visualized by confocal microscopy. Scale bar, 50 μm. Focal adhesion size was measured by Fiji program.	28494858 24126619 21965657 28757207
Immunofluorescence	lipin-1; PubMed: 28347999 FASEB J Inhibition of mTOR activity promoted the nuclear translocation of lipin-1. After treatment with or without torin 1 for 4 h, cells expressing HA-lipin-1 were fixed and stained with a rabbit HA antibody followed by Alexa 594–conjugated goat anti-rabbit secondary antibody. Nuclei were stained with DAPI. Scale bars, 20 μM.	28347999
Growth inhibition assay	Cell viability; PubMed: 28757207 Mol Cell Cancer cell lines were grown in complete media with/without mTOR inhibitor, Torin1 (250 nM). Media and Torin1 were replaced every 2 days and cells were counted at the indicated time points. Data are the means ± SD of three separate experiments performed in triplicate.	28757207

In vivo

Torin1 is efficacious at a dose of 20 mg/kg in a U87MG xenograft model and demonstrates good pharmacodynamic inhibition of downstream effectors of mTOR in tumor and peripheral tissues. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse mTORC1 and mTORC2 in Vitro Kinase Assays: To produce soluble mTORC1, HEK-293T cell lines that stably express N-terminally FLAG-tagged Raptor are generated using vesicular stomatitis virus G-pseudotyped MSCV retrovirus. For mTORC2, similar HeLa cells that stably express N-terminally FLAG-tagged Protor-1 are generated. Both complexes are purified by lysing cells in 50 mm HEPES, pH 7.4, 10 mm sodium pyrophosphate, 10 mm sodium β-glycerophosphate, 100 mm NaCl, 2 mm EDTA, 0.3% CHAPS. Cells are lysed at 4 °C for 30 min, and the insoluble fraction is removed by microcentrifugation at 13,000 rpm for 10 min. Supernatants are incubated with FLAG-M2 monoclonal antibody-agarose for 1 h and then washed three times with lysis buffer and once with lysis buffer containing a final concentration of 0.5 M NaCl. Purified mTORC1 is eluted with 100 μg/mL 3×FLAG peptide in 50 mm HEPES, pH 7.4, 100 mm NaCl. Eluate can be aliquoted and stored at -80 °C. Substrates S6K1 and Akt1 are purified. Kinase assays are performed for 20 min at 30 °C in a final volume of 20 μL consisting of the kinase buffer (25 mm HEPES, pH 7.4, 50 mm KCl, 10 mm MgCl₂, 500 μm ATP) and 150 ng of inactive S6K1 or Akt1 as substrates. Reactions are stopped by the addition of 80 μL of sample buffer and boiled for 5 min. Samples are subsequently analyzed by SDS-PAGE and immunoblotting.
Cell Research:^[1]	- Collapse Cell lines: MEFs Concentrations: ~250 nM Incubation Time: 4 days Method: Cell viability is assessed with the CellTiter-Glo Luminescent Cell Viability Assay. On Day 0, 96-well plates are seeded with 500 cells per well and grown overnight. On Day 1, cells are treated with the appropriate compounds and subsequently analyzed on Days 3-5. For analysis, plates are incubated for 60 min at room temperature; 50 μL of CellTiter-Glo reagent is added to each well, and plates are mixed on an orbital shaker for 12 min. Luminescence is quantified on a standard plate luminometer. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: U87MG xenograft model Dosages: 20 mg/kg Administration: Administered via i.p. once daily (Only for Reference)

References

[4] Dowling RJ, et al, Science, 2010, 328(5982), 1172-1176.

- Collapse

Solubility (25°C)

In vitro	DMSO	2 mg/mL (3.29 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 20% NMP+50% PEG 400 For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Torin 1 SDF

Molecular Weight	607.62
Formula	C₃₅H₂₈F₃N₅O₂
CAS No.	1222998-36-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	CCC(=O)N1CCN(CC1)C2=CC=C(C=C2C(F)(F)F)N3C(=O)C=CC4=C3C5=CC(=CC=C5N=C4)C6=CC7=CC=CC=C7N=C6

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to re-constitute the inhibitor for i.p. administration?
Answer:
S2827 Torin 1 can be dissolved in 5% DMSO/30% PEG 300/ddH2O at 0.25 mg/ml clearly, and in 10% DMSO/corn oil at 0.5 mg/ml, it is also a clear solution.

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Selective mTOR inhibitor

Rapamycin (Sirolimus) : mTORC1-selective, IC50=~0.1 nM.
Most Potent mTOR Inhibitor

Rapamycin (Sirolimus) : mTOR, IC50=~0.1 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

Related mTOR Products

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay. Everolimus induces cell apoptosis and autophagy and inhibits tumor cells proliferation.
AZD8055

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Features:First drug to inhibit both types of mTOR protein.
Temsirolimus (CCI-779)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.
Sapanisertib (MLN0128)

Sapanisertib (INK 128, MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Tacrolimus (FK506)

Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.
KU-0063794

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Choose Your Country or Region

By Signaling Pathways

By product type

Torin 1